Literature DB >> 24405697

Alternative tacrolimus and sirolimus regimen associated with rapid resolution of posterior reversible encephalopathy syndrome after lung transplantation.

Don Hayes1, Brent Adler2, Tiffany L Turner3, Heidi M Mansour4.   

Abstract

BACKGROUND: Neurotoxicity is a significant complication of calcineurin inhibitor use, and posterior reversible encephalopathy syndrome has been reported. Limited data exist on the use of alternative immunosuppression regimens in the management of posterior reversible encephalopathy syndrome in transplant recipients.
METHODS: We present the immunosuppression management strategy of a girl who underwent bilateral lung transplantation for cystic fibrosis 6 months earlier, then suddenly developed a grand mal seizure due to posterior reversible encephalopathy syndrome diagnosed by magnetic resonance imaging of the brain. In an effort to reduce her tacrolimus dose, an alternative immunosuppressant regimen combining tacrolimus and sirolimus was used.
RESULTS: After the modification of her immunosuppressant regimen, there was rapid clinical improvement with no further seizures. Her brain findings had resolved on magnetic resonance imaging 2 months later. Over the next 6 months, allograft function remained stable and surveillance transbronchial biopsies found no allograft rejection on the combined sirolimus and tacrolimus therapy.
CONCLUSIONS: Tacrolimus-associated neurotoxicity resolved in a lung transplant recipient with a combined tacrolimus and sirolimus regimen. This combined therapy appears to be an effective alternative for lung transplant recipients that allow them to receive the benefits of both drugs but at lower doses, which reduces the risk for adverse effects.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  lung transplantation; posterior reversible encephalopathy syndrome; sirolimus; tacrolimus

Mesh:

Substances:

Year:  2013        PMID: 24405697     DOI: 10.1016/j.pediatrneurol.2013.11.006

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  7 in total

Review 1.  [Posterior reversible encephalopathy syndrome].

Authors:  M Fischer; E Schmutzhard
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-06-06       Impact factor: 0.840

Review 2.  New Developments in Hypertensive Encephalopathy.

Authors:  Joseph B Miller; Kushak Suchdev; Namita Jayaprakash; Daniel Hrabec; Aditya Sood; Snigdha Sharma; Phillip D Levy
Journal:  Curr Hypertens Rep       Date:  2018-02-26       Impact factor: 5.369

Review 3.  Posterior Reversible Encephalopathy Syndrome After Transplantation: a Review.

Authors:  Sheng Chen; Jun Hu; Liang Xu; Dixon Brandon; Jun Yu; Jianmin Zhang
Journal:  Mol Neurobiol       Date:  2015-12-14       Impact factor: 5.590

4.  A Case of Synthetic Cannabinoid (K2)-Induced Posterior Reversible Encephalopathy Syndrome (PRES).

Authors:  Haider Ghazanfar; Aruna Muthumanickam; Zaheer Qureshi; Faryal Altaf; Cosmina Zeana; Sridhar Chilimuri
Journal:  Am J Case Rep       Date:  2022-04-26

Review 5.  Calcineurin Inhibitors Associated Posterior Reversible Encephalopathy Syndrome in Solid Organ Transplantation: Report of 2 Cases and Literature Review.

Authors:  Turun Song; Zhengsheng Rao; Qiling Tan; Yang Qiu; Jinpeng Liu; Zhongli Huang; Xianding Wang; Tao Lin
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

6.  Tacrolimus-induced parkinsonism in a patient after liver transplantation - case report.

Authors:  Karin Gmitterová; Michal Minár; Miroslav Žigrai; Zuzana Košutzká; Alice Kušnírová; Peter Valkovič
Journal:  BMC Neurol       Date:  2018-04-20       Impact factor: 2.474

7.  Immunosuppression-associated posterior reversible encephalopathy syndrome in an acute leukemia case.

Authors:  Umit Y Malkan; Gursel Gunes; Haluk Demiroglu; Hakan Goker
Journal:  Hematol Rep       Date:  2018-11-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.